PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Status:
Completed
Trial end date:
2018-12-15
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate 2-year disease-free survival in this patient
population treated with single agent cisplatin and patients treated with cisplatin in
combination with Rucaparib following preoperative chemotherapy. Side effects and tolerability
of this treatment in patients with residual disease following preoperative chemotherapy will
also be observed and characterized.